Navigation Links
FDA Continues Review of Takeda's New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes
Date:10/10/2008

previous two to three months. Alogliptin was generally well-tolerated and weight neutral. There was no increase in hypoglycemia compared to placebo.

About DPP-4 Inhibitors

DPP-4 inhibitors inhibit the enzyme dipeptidyl peptidase-4 (DPP-4), which selectively metabolizes the insulin-increasing hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). By maintaining the blood levels of GLP-1 and GIP, DPP-4 inhibitors are a new type of oral anti-diabetic with a novel mechanism of action for lowering blood sugar levels. GLP-1 and GIP are excreted in the digestive tract following food intake, and stimulate the beta-cells in the pancreas --- thereby stimulating increased insulin secretion --- and it has also been confirmed that they improve the functioning of the beta cells themselves. Furthermore it is known that because GLP-1 suppresses glucagon secretion from the pancreas, the production of sugar in liver cells is also suppressed and appetite is suppressed as well.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda (TSE:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com.


'/>"/>
SOURCE Takeda Pharmaceutical Company Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets
2. Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis?
3. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
4. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
5. InstaCare Corp. Continues Turnaround & Reports 291% Revenues Increase in 2Q 2008
6. The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future
7. Cystic Fibrosis - Axentis Pharma Takes Over Patents and Continues Development of Innovative Platform Technology
8. Gerresheimer Discontinues Marginal Operations
9. 3M Discontinues Collaboration with Gen-Probe to Develop Molecular Tests for Healthcare-Associated Infections
10. HDSA-San Diegos Team 2CureHD Continues its Race to Cure Huntingtons Disease
11. Tasty Baking Company Continues Partnership With Alexs Lemonade Stand Foundation To Fight Childhood Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, ... host a conference call to provide an update ... p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and ... Live web cast: www.neurotropebioscience.com , under "Investor Relations"The ... after completion through September 2, 2014 at (888) ...
(Date:8/20/2014)... Toronto, Canada (PRWEB) August 20, 2014 ... wisdom that E&L studies should be performed late in ... system is known. But current regulatory trends suggest that, ... are on the rise. In recent years, multiple drug ... E&L packages or address specific questions during phase I/II. ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 One ... regenerative medicine is an inadequate vascular supply. Nutrient ... and decellularized tissues is critical for successful regeneration ... attempted to mitigate deficiencies in vascularization and promote ... scaffold bioactivity, optimizing scaffold design and architecture, and ...
(Date:8/19/2014)... , Aug. 19, 2014 Research and ... Fuel Cells (SOFCs) - Global Strategic Business Report" report ... worldwide markets for Solid Oxide Fuel Cells (SOFCs) in US$ ... Canada , Europe , ... estimates and forecasts are provided for the period 2012 through ...
Breaking Biology Technology:Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2
... Tectonics Corporation,s (Amex: ETC ) ("ETC" or ... of two BARA-MED(R)XD Monoplace hyperbaric oxygen chambers in the ... state-of-the-art monoplace chambers are the first computer-controlled hyperbaric chambers ... , Hyperbaric oxygen (HBO) ...
... REYKJAVIK, Iceland, Dec. 8 deCODE genetics,(Nasdaq: ... an international consortium of,scientists from deCODE and major ... variation in the human genome (SNP) that is ... type 2 diabetes (T2D). deCODE,will employ its CLIA-registered ...
... NVAX ) today announced that the Company will hold ... human clinical trial in,healthy adult subjects of Novavax,s seasonal influenza ... 2008. , The call ... Rahul Singhvi and other members of senior management, including Chief,Medical ...
Cached Biology Technology:Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma 2Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma 3Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma 4deCODE to Integrate New Genetic Risk Factor for Type 2 Diabetes Into Its deCODEme(TM) Personal Genome Scan Service 2deCODE to Integrate New Genetic Risk Factor for Type 2 Diabetes Into Its deCODEme(TM) Personal Genome Scan Service 3deCODE to Integrate New Genetic Risk Factor for Type 2 Diabetes Into Its deCODEme(TM) Personal Genome Scan Service 4Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008 2
(Date:8/21/2014)... of radiations in the 3.3 to 4.4 nanometre range, ... tissues. New theoretical findings show that it is possible ... could be the basis of an optimal technique to ... to be used in high-precision spectroscopy. Now, a new ... generate the harmonic radiationswhich are multiples of an incoming ...
(Date:8/21/2014)... successfully replicated one of the crucial steps in photosynthesis, ... which could manufacture hydrogen as a fuel. , "Water ... exciting prospect to use them to create hydrogen, and ... from the ARC Centre of Excellence for Translational Photosynthesis ... offers potential as a zero-carbon replacement for petroleum products, ...
(Date:8/20/2014)... Huntsman Cancer Institute (HCI) at the University of Utah ... that encodes BCR-ABL, the unregulated enzyme driving the blood ... Cancer Society, nearly 6,000 new cases of CML will ... called tyrosine kinase inhibitors (TKIs), target BCR-ABL and are ... CML but control it in a way that allows ...
Breaking Biology News(10 mins):Water window imaging opportunity 2Water and sunlight the formula for sustainable fuel 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... cousin of the humble mustard plant, scientists at the ... big surprise while investigating how plants respond to attacks ... "Contrary to what we thought we'd find, our experiments ... concert with one another in tug-of war or teeter ...
... statistical method is a more reliable way to map ... potential cancer treatment targets, according to new Brown University ... a promising new tool for tracing human gene connections, ... other diseases. Results appeared this week in the online ...
... the humble mustard plant, scientists at the University of ... while investigating how plants respond to attacks from disease ... what we thought we'd find, our experiments showed that ... one another in tug-of war or teeter totter-fashion to ...
Cached Biology News:FDA approves more generic AIDS drugs 2FDA approves more generic AIDS drugs 3Researchers develop promising new gene network analysis method 2UNC plant researchers discover proteins interact to form hair-trigger protection against invaders 2UNC plant researchers discover proteins interact to form hair-trigger protection against invaders 3
Pancreatic Cell Cryopreservation Medium (2X) is intended for the cryopreservation of LT2 Immortalized Pancreatic Mesenchymal Cells (SCR013) and VIT1 Primary Pancreatic Mesenchymal Cells (SCR014)....
LAB/Probe Mouse-Rabbit DAB Kit...
Mouse monoclonal [SH-A1] to S100 alpha ( Abpromise for all tested applications). entrezGeneID: 6271 SwissProtID: P23297...
G-protein coupled purinergic receptor P2Y8...
Biology Products: